LNTH: Lantheus Holdings Inc. is our featured asset today. Trading this asset between 2021-07-02 and 2023-06-22 with our AI strategy, investors could have potentially made a 347.01% return on average. The average trade made 49.57% and was held for 89.0 days. A total of 7 positions were taken over the period. Our trading idea suggests that LNTH is a STRONGBUY since 2023-11-09 at a buy price target of 66.41. This prediction is based on a model with an overall accuracy of 0.73 when predicting an upward trend in the following 2 weeks. The analyst consensus price target is 100.86.
Lantheus Holdings Inc., stock symbol LNTH, is a global diagnostic and therapeutic agent and product developer, manufacturer, and marketer headquartered in North Billerica, Massachusetts. The company is listed on the NASDAQ and trades in the United States in USD. Lantheus is part of the Life Sciences sector and the In Vitro & In Vivo Diagnostic Substances industry.
The company has a market capitalization of 3979872000 USD and an EBITDA of 291142000 USD. The current price of the stock is 66.41 USD, while the trailing price-to-earnings (PE) ratio is 39.6 and the forward PE ratio is 31.45. The price-to-sales ratio is 4.518, while the price-to-book ratio is 5.87. The EV-to-revenue ratio is 4.579 and the EV-to-EBITDA ratio is 16.96. The company has a beta of 0.786.
Lantheus has a 52-week high of 87.47 USD and a 52-week low of 28.47 USD. The 50-day moving average is 54.28 USD and the 200-day moving average is 65.84 USD. As of the date of this article, the company has 68832000 shares outstanding.
In terms of historic performance, the company has reported a quarterly earnings growth year-over-year of 3.692% and quarterly revenue growth year-over-year of 1.344%. The profit margin is 0.134 and the operating margin is 0.303. The return on assets is 0.156 and the return on equity is 0.188. The TTM revenue per share is 11.74 USD and the TTM gross profit is 187695000 USD. The TTM EPS is 1.46 USD and the TTM diluted EPS is also 1.46 USD.
The company does not pay a dividend, and there is no dividend date or ex-dividend date. The analyst target price is 100.86 USD.
In conclusion, Lantheus Holdings Inc., stock symbol LNTH, is a global diagnostic and therapeutic agent and product developer, manufacturer, and marketer headquartered in North Billerica, Massachusetts. The company has a market capitalization of 3979872000 USD and an EBITDA of 291142000 USD, and the current stock price is 66.41 USD. The company has shown strong quarterly earnings growth year-over-year and quarterly revenue growth year-over-year. The analyst target price is 100.86 USD.
AssetType: Common Stock
Name: Lantheus Holdings Inc
Description: Lantheus Holdings, Inc. develops, manufactures and markets diagnostic and therapeutic agents and products that assist physicians in the diagnosis and treatment of heart, cancer and other diseases worldwide. The company is headquartered in North Billerica, Massachusetts.
Sector: LIFE SCIENCES
Industry: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Address: 331 TREBLE COVE ROAD, NORTH BILLERICA, MA, US
|Date||Symbol||Prediction||Model Accuracy||Price Target||Analyst Target|
More AI Trading NASDAQ Fri, 10 Nov buys
AI Trading NASDAQ Fri, 10 Nov sells
Back-testing and model summaries
Thanks for subscribing and happy investing!
The Third Perspective Team